Ontology highlight
ABSTRACT: Background
The social stigma and chronicity of psoriasis significantly affect health-related quality of life (HRQoL).Objective
We examined the effect of three regimens of secukinumab on HRQoL in moderate to severe psoriasis patients.Methods
Twelve-week data from a phase II, randomized, double-blind, placebo-controlled, regimen-finding study evaluated HRQoL, measured by the Dermatology Life Quality Index (DLQI). Secukinumab or placebo was administered subcutaneously in three treatment regimens: single (baseline only), monthly (baseline, weeks 4, 8) and early (baseline, weeks 1, 2, 4). Differences among regimens were assessed with logistic regression models and Fisher's exact test.Results
Patients (n = 404) were randomized to single (baseline) treatment regime
SUBMITTER: Augustin M
PROVIDER: S-EPMC4814339 | biostudies-literature | 2016 Apr
REPOSITORIES: biostudies-literature